Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Oxford Lane Capital Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Oxford Lane Capital Corp trades at $9.23 (market cap $891.54M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 44.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 26.29% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | OXLC | |
|---|---|---|
Market Cap | $39.89B | $891.54M |
Sector | Health | Financials |
52-Week High | $491.22 | $20.80 |
52-Week Low | $278.09 | $8.15 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 26.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
OXLC trades at $9.13, up 0.66% today, with a mixed technical outlook showing bullish moving averages but overbought RSI readings. The company reported a net income margin exceeding 100% for 2025, yet recent quarterly earnings have consistently missed expectations, including a significant loss in Q1 2026. Dividend payments remain active, but negative ROE and ROA highlight financial strain. Analyst sentiment is divided, with a 50% buy rating amid concerns over net asset value declines and high distribution yields.
The outlook for OXLC is clouded by severe profitability challenges and volatile earnings, presenting high risk. While the dividend yield attracts income seekers, sustained NAV erosion and operational cash outflows signal underlying weakness. Investment opportunity hinges on a turnaround in CLO equity markets, but current fundamentals suggest caution is warranted for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
